Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

The cervical cancer vaccine could prevent even more cases of the disease in England than previously thought, UK scientists have found.

15 Jul 2010

Highlights of AAPM 52nd meeting

The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.

14 Jul 2010

QIAGEN's digene HPV Test improves cervical cancer control: Study

A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.

From QIAGEN Manchester Limited 13 Jul 2010

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests.

13 Jul 2010

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

Vaccine manufacturers in India and other developing countries may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers at the Duke Institute for Genome Sciences & Policy. At a cost of at least $300 for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil- from Merck and Cervarix- from GlaxoSmithKline, are some of the most expensive ever introduced.

12 Jul 2010

HPV DNA testing for precancer, cervical cancer is more sensitive than cytology testing: Study

HPV DNA testing for precancers and cervical cancers is over 50 per cent more sensitive than cytology testing for the same conditions a community-based study in Mexico has revealed. Results of the largest HPV DNA primary screening study ever to be performed in a Latin American country point to the readiness of HPV DNA testing for large-scale implementation in Mexico and are published online today (8 July 2010) in Cancer, Causes and Controls.

9 Jul 2010

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Roche today announced that data from the ATHENA (Addressing THE Need for Advanced HPV Diagnostics) U.S. registration trial of over 47,000 women demonstrate that two human papillomavirus genotypes, HPV 16 and HPV 18, can identify those women with cervical pre-cancer missed by cytologic examination with a Papanicolau (Pap) test.

From Roche Sequencing and Life Science 9 Jul 2010

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

8 Jul 2010

QIAGEN receives CE conformity marking for careHPV Test

QIAGEN has completed European certification of its careHPV™ Test to bring human papillomavirus (HPV) testing to public-health programs in low-resource, developing countries, the company announced today at the International Papillomavirus Conference in Montreal, Canada. The CE conformity marking ("Conformite Europeenne") certifies that the careHPV Test has met European Union consumer safety and health requirements, allowing the test to be distributed in developing countries that recognize the CE mark.

From QIAGEN Manchester Limited 7 Jul 2010

Hologic enters definitive agreement to acquire Sentinelle Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc., a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

From Hologic, Inc. 7 Jul 2010

International conference focuses on HPV's impact on women

Scientists, clinicians and public health leaders from around the world are gathered in Montreal this week for the 26th International Papillomavirus Conference where they hope to generate awareness about human papillomavirus, Canwest News Service/Gazette reports (Martin/McCallum, 7/4).

7 Jul 2010

Mass vaccination has reduced the incidence of genital warts by 60%: Report

Genital warts, commonly caused by human papillomavirus (HPV) are on the decline after routine vaccination of Australian women with a vaccine against HPV. The sexual partners of these women are also beneficiaries of the vaccine.

5 Jul 2010

Experts urge community to get behind bowel cancer screening

University of Sydney experts say around 1000 bowel cancer deaths could be prevented every year if a fully-funded, evidence-based bowel cancer screening program was implemented by the Australian Government.

5 Jul 2010

New guide to get pregnant

Infertility affects about 7 million Americans -- that's about one in six couples during their childbearing years. There are many reasons for infertility, with equal chances it's his medical issue as it is hers. A new book, "A Baby at Last!: The Couples' Complete Guide to Getting Pregnant" (Fireside Books, Simon and Schuster), points the way for couples to get past the emotionally wrenching obstacle of infertility and finally bring home their bundle of joy.

1 Jul 2010

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

Gen-Probe Incorporated announced today that it has received a European CE mark for its APTIMA® assay for Trichomonas vaginalis, a common parasitic sexually transmitted disease.

1 Jul 2010

U.S., China open Shanghai Epidemiology Center for chronic, epidemic diseases

Chinese and U.S. health officials opened an epidemiology center in Shanghai Tuesday to train experts to deal with and prevent chronic and epidemic diseases, the Associated Press reports.

30 Jun 2010

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Zila, leader in the prevention and detection of oral diseases, today introduced an angled exam mirror as part of the ViziLite Plus oral lesion identification and marking system. The autoclavable mirror attaches to the top of the ViziLite Plus lightstick retractor, enhancing dental professionals' ability to see oral lesions during a comprehensive oral cancer screening procedure.

28 Jun 2010

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010

New poll illustrates difficult situations cancer patients face in affording needed health care

A new poll illustrates the difficulty that cancer patients, survivors and their families face in affording needed health care and paying for other basic necessities such as food and heat, underscoring the need to strongly implement the Affordable Care Act so that it works for people with cancer.

24 Jun 2010

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

Helix BioPharma Corp. today announced positive Phase II pharmacokinetic findings for Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

24 Jun 2010

Cervical Cancer News and Research

Further Reading

Cervical cancer vaccine could reduce number of cases from 3,000 to less than 700 every year

Highlights of AAPM 52nd meeting

QIAGEN's digene HPV Test improves cervical cancer control: Study

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

Vaccine manufacturers may be able to produce lower-cost HPV vaccines, say researchers

HPV DNA testing for precancer, cervical cancer is more sensitive than cytology testing: Study

Screening for HPV genotypes 16 and 18 helps detect cervical pre-cancer missed by Pap test

Clinical performance data of Cervista HPV HR presented at International Papillomavirus Conference

QIAGEN receives CE conformity marking for careHPV Test

Hologic enters definitive agreement to acquire Sentinelle Medical

International conference focuses on HPV's impact on women

Mass vaccination has reduced the incidence of genital warts by 60%: Report

Experts urge community to get behind bowel cancer screening

New guide to get pregnant

Gen-Probe's APTIMA Trichomonas assay receives European CE mark

U.S., China open Shanghai Epidemiology Center for chronic, epidemic diseases

Zila introduces angled exam mirror as part of ViziLite Plus oral lesion identification and marking system

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

New poll illustrates difficult situations cancer patients face in affording needed health care

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News